Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ilaris

- PMLiVE

WHO reports new Omicron subvariant cases detected in 29 countries worldwide

The new Omicron subvariant is spreading rapidly in the US

- PMLiVE

Valneva reports additional data for COVID-19 booster

VLA2001 was well tolerated in participants previously vaccinated with an mRNA vaccine

- PMLiVE

Novavax initiates phase 2 combination COVID-19/flu vaccine study

Initial results from the trial are expected towards the middle of the year

- PMLiVE

RQ Bio-discovered antibody enters clinic as part of AstraZeneca COVID-19 study

The trial will evaluate the UK-based biotech’s AZD3152 in combination with cilgavimab

- PMLiVE

Roche’s COVID-19 antibody receives FDA approval for hospitalised adults

The decision makes Actemra the first FDA-approved monoclonal antibody to treat COVID-19

- PMLiVE

CHMP recommends use of Moderna’s Omicron BA.1 booster in children in the EU

The company is also evaluating the use of the vaccine in children aged from six months

- PMLiVE

WHO joins calls for equitable access to healthcare products ahead of future pandemics

The WHO, WIPO and WTO gathered at the Joint Technical Symposium on 16 December

- PMLiVE

Novartis receives EC approval for Pluvicto to treat adult cancer patients

Patients receiving Pluvicto plus best standard of care had a 38% reduction in the risk of death

- PMLiVE

Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study

Around 82.3% of patients achieved haemoglobin-level increases of 2g/dL or more from baseline

- PMLiVE

Novartis partners with Cancer Research UK for rare cancer trial

The trial enrolled both paediatric and adult patients with any rare form of cancer

- PMLiVE

WHO member states commit to producing a pandemic accord in 2023

The ‘zero draft’ will be a legally binding agreement, part of the WHO Constitution

- PMLiVE

UK Government launches new taskforce to help NHS tackle COVID-19 backlogs

Experts will focus on how the NHS can utilise existing capacity in the independent sector

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links